Cardiac Safety and Trauma Trial Design Subject Of Hemopure Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Blood Products Advisory Committee review could give the agency the green light to lift the clinical hold on the hemoglobin-based oxygen therapeutic.
You may also be interested in...
U.S. Navy Plans To Proceed With Hemopure Development
Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.
U.S. Navy Plans To Proceed With Hemopure Development
Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.
Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study
Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.